exenatide ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
peptides and glycopeptides 1123 141758-74-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • exenatide
  • byetta
  • exenatide synthetic
  • bydureon
  • exendin-4
  • AC002993
  • AC2993A
A synthetic form of exendin-4, a 39-amino acid peptide isolated from the venom of the Gila monster lizard (Heloderma suspectum). Exenatide increases CYCLIC AMP levels in pancreatic acinar cells and acts as a GLUCAGON-LIKE PEPTIDE-1 RECEPTOR (GLP-1) agonist and incretin mimetic, enhancing insulin secretion in response to increased glucose levels; it also suppresses inappropriate glucagon secretion and slows gastric emptying. It is used an anti-diabetic and anti-obesity agent.
  • Molecular weight: 4186.63
  • Formula: C184H282N50O60S
  • CLOGP:
  • LIPINSKI: None
  • HAC: 110
  • HDO: 58
  • TPSA: 1749.75
  • ALOGS:
  • ROTB: 134

Drug dosage:

DoseUnitRoute
0.29 mg P
15 mcg P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 25 mg/mL Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.00 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

DateAgencyCompanyOrphan
April 28, 2005 FDA ASTRAZENECA AB

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pancreatitis 2019.55 16.85 736 22715 48319 63417252
Blood glucose increased 1915.12 16.85 821 22630 82935 63382636
Weight decreased 1138.37 16.85 884 22567 275914 63189657
Injection site nodule 958.52 16.85 233 23218 3602 63461969
Nausea 566.91 16.85 1072 22379 853399 62612172
Blood glucose decreased 562.31 16.85 231 23220 20721 63444850
Pancreatitis acute 382.47 16.85 191 23260 26975 63438596
Injection site haemorrhage 354.27 16.85 175 23276 24139 63441432
Injection site pruritus 352.34 16.85 215 23236 44901 63420670
Injection site mass 334.91 16.85 155 23296 18501 63447070
Glycosylated haemoglobin increased 316.61 16.85 132 23319 12266 63453305
Injection site extravasation 276.87 16.85 109 23342 8732 63456839
Injection site pain 237.02 16.85 265 23186 129535 63336036
Injection site urticaria 213 16.85 104 23347 13969 63451602
Vomiting 211.59 16.85 564 22887 559053 62906518
Incorrect dose administered by device 207.33 16.85 73 23378 4275 63461296
Device leakage 206.55 16.85 83 23368 7013 63458558
Hypoglycaemia 196.79 16.85 169 23282 59896 63405675
Injection site erythema 178.38 16.85 185 23266 82989 63382582
Decreased appetite 176.48 16.85 325 23126 250727 63214844
Wrong technique in device usage process 173.82 16.85 61 23390 3537 63462034
Injection site rash 168.49 16.85 98 23353 18711 63446860
Blood glucose abnormal 168.35 16.85 74 23377 7818 63457753
Injection site bruising 160.27 16.85 129 23322 41781 63423790
Pancreatic carcinoma 154.59 16.85 69 23382 7559 63458012
Lipase increased 125.80 16.85 65 23386 9835 63455736
Blood glucose fluctuation 124.50 16.85 51 23400 4525 63461046
Device delivery system issue 119.49 16.85 32 23419 737 63464834
Device malfunction 116.47 16.85 76 23375 17781 63447790
Injection site irritation 113.74 16.85 49 23402 4929 63460642
Incorrect dose administered 113.68 16.85 125 23326 59843 63405728
Early satiety 106.84 16.85 31 23420 965 63464606
Diabetic ketoacidosis 104.63 16.85 75 23376 20430 63445141
Pancreatitis chronic 104.45 16.85 38 23413 2446 63463125
Diabetes mellitus inadequate control 100.17 16.85 65 23386 15061 63450510
Product quality issue 99.67 16.85 92 23359 35773 63429798
Cholelithiasis 98.24 16.85 100 23351 43825 63421746
Intentional device misuse 90.46 16.85 26 23425 782 63464789
Pancreatic carcinoma metastatic 79.39 16.85 30 23421 2148 63463423
Infusion related reaction 77.63 16.85 3 23448 245518 63220053
Injury associated with device 76.97 16.85 34 23417 3632 63461939
Hyperglycaemia 73.72 16.85 84 23367 41783 63423788
Injection site swelling 73.07 16.85 89 23362 47483 63418088
Impaired gastric emptying 72.36 16.85 46 23405 10286 63455285
Eructation 70.87 16.85 42 23409 8291 63457280
Urticaria 70.26 16.85 175 23276 165627 63299944
Device issue 69.97 16.85 63 23388 23718 63441853
Underdose 67.83 16.85 66 23385 27390 63438181
Pain 67.67 16.85 106 23345 740522 62725049
Drug ineffective 66.51 16.85 184 23267 1044581 62420990
Joint swelling 63.46 16.85 21 23430 327645 63137926
Systemic lupus erythematosus 61.44 16.85 4 23447 208914 63256657
Drug intolerance 59.39 16.85 20 23431 308641 63156930
Amylase increased 59.30 16.85 34 23417 6311 63459260
Adenocarcinoma pancreas 58.74 16.85 20 23431 1058 63464513
Treatment failure 57.98 16.85 4 23447 199039 63266532
Toxicity to various agents 55.11 16.85 12 23439 247238 63218333
Nodule 54.68 16.85 52 23399 20974 63444597
Lactic acidosis 54.57 16.85 69 23382 38218 63427353
Device use issue 53.95 16.85 24 23427 2606 63462965
Needle issue 53.03 16.85 38 23413 10338 63455233
Arthralgia 52.46 16.85 81 23370 569629 62895942
Rheumatoid arthritis 51.40 16.85 15 23436 253804 63211767
Acute kidney injury 50.69 16.85 212 23239 263203 63202368
Blood triglycerides increased 48.89 16.85 39 23412 12449 63453122
Wound 48.37 16.85 3 23448 163260 63302311
Musculoskeletal stiffness 47.69 16.85 6 23445 184612 63280959
Arthropathy 47.31 16.85 14 23437 234778 63230793
Dehydration 46.24 16.85 155 23296 173199 63292372
Pyrexia 46.11 16.85 64 23387 470414 62995157
Abdominal pain 45.10 16.85 221 23230 293235 63172336
Pneumonia 44.89 16.85 62 23389 456705 63008866
Neutropenia 44.45 16.85 6 23445 174999 63290572
Increased appetite 44.09 16.85 33 23418 9597 63455974
Fatigue 43.57 16.85 175 23276 887853 62577718
Pancreatitis necrotising 42.92 16.85 18 23433 1694 63463877
Circumstance or information capable of leading to medication error 42.34 16.85 23 23428 3847 63461724
Injection site haematoma 41.92 16.85 28 23423 6804 63458767
Injection site abscess 41.85 16.85 16 23435 1182 63464389
Hunger 40.31 16.85 25 23426 5354 63460217
Injection site inflammation 39.73 16.85 22 23429 3821 63461750
Death 39.67 16.85 48 23403 374333 63091238
Infection 38.88 16.85 18 23433 229155 63236416
General physical health deterioration 35.45 16.85 15 23436 201387 63264184
Hepatic steatosis 35.03 16.85 48 23403 28721 63436850
Alopecia 34.99 16.85 44 23407 337492 63128079
White blood cell count decreased 34.78 16.85 5 23446 139099 63326472
Peripheral swelling 33.95 16.85 29 23422 265913 63199658
Intentional product use issue 33.40 16.85 4 23447 127888 63337683
Abdominal distension 33.10 16.85 88 23363 86527 63379044
Feeling jittery 32.69 16.85 32 23419 13371 63452200
Nasopharyngitis 32.12 16.85 28 23423 254229 63211342
Medication error 32.04 16.85 64 23387 52220 63413351
Pancreatitis relapsing 31.24 16.85 12 23439 898 63464673
Device defective 31.18 16.85 15 23436 1947 63463624
Product use in unapproved indication 30.47 16.85 14 23437 179066 63286505
Thrombocytopenia 30.45 16.85 9 23442 151148 63314423
Stomatitis 30.35 16.85 7 23444 138718 63326853
Injection site induration 30.25 16.85 26 23425 9200 63456371
Febrile neutropenia 30.22 16.85 4 23447 118445 63347126
Discomfort 30.20 16.85 12 23439 167362 63298209
Product dose omission issue 28.80 16.85 166 23285 234147 63231424
Sinusitis 28.58 16.85 25 23426 226628 63238943
Injection site cellulitis 27.52 16.85 12 23439 1242 63464329
Thyroid cancer 27.42 16.85 20 23431 5591 63459980
Swelling 26.39 16.85 38 23413 275340 63190231
Therapeutic product effect incomplete 26.02 16.85 7 23444 125049 63340522
Product quality control issue 25.92 16.85 5 23446 23 63465548
Disease progression 25.30 16.85 7 23444 122751 63342820
Body mass index abnormal 25.14 16.85 6 23445 85 63465486
Injection site indentation 24.80 16.85 7 23444 197 63465374
Product use issue 24.70 16.85 27 23424 220493 63245078
Hepatic enzyme increased 24.69 16.85 23 23428 202305 63263266
Renal failure 24.40 16.85 97 23354 117555 63348016
Cough 23.77 16.85 45 23406 292698 63172873
Vomiting projectile 23.41 16.85 11 23440 1355 63464216
Injection site warmth 22.63 16.85 28 23423 15167 63450404
Cholecystitis 22.36 16.85 28 23423 15349 63450222
Hypoglycaemic unconsciousness 22.30 16.85 9 23442 768 63464803
Bile duct stent insertion 21.87 16.85 5 23446 58 63465513
Pancreatitis haemorrhagic 21.84 16.85 8 23443 525 63465046
Helicobacter infection 21.70 16.85 4 23447 92781 63372790
Pancreatic duct stenosis 21.57 16.85 5 23446 62 63465509
Loss of personal independence in daily activities 21.10 16.85 5 23446 97285 63368286
Dyspnoea 20.83 16.85 151 23300 661162 62804409
Intestinal malrotation 20.51 16.85 7 23444 373 63465198
C-reactive protein increased 20.27 16.85 5 23446 94702 63370869
Medullary thyroid cancer 19.87 16.85 6 23445 215 63465356
Injection site infection 19.75 16.85 11 23440 1932 63463639
Angioedema 19.61 16.85 50 23401 47915 63417656
Confusional state 19.47 16.85 36 23415 236344 63229227
Pancreatic neoplasm 19.22 16.85 8 23443 738 63464833
Injection site reaction 18.95 16.85 56 23395 58468 63407103
Congenital intestinal malformation 18.84 16.85 4 23447 32 63465539
Product dispensing error 18.68 16.85 21 23430 10284 63455287
Platelet count decreased 18.35 16.85 10 23441 116112 63349459
Mobility decreased 18.34 16.85 11 23440 121148 63344423
Product prescribing error 18.33 16.85 34 23417 26255 63439316
Metastases to liver 18.30 16.85 32 23419 23607 63441964
Nail growth abnormal 18.04 16.85 7 23444 538 63465033
Condition aggravated 17.93 16.85 82 23369 402135 63063436
Gait disturbance 17.81 16.85 25 23426 183153 63282418
Glycosylated haemoglobin decreased 17.79 16.85 7 23444 559 63465012
Feeling abnormal 17.47 16.85 104 23347 148288 63317283
Hyponatraemia 17.16 16.85 10 23441 111890 63353681
Weight increased 17.09 16.85 159 23292 260633 63204938
Product administration error 16.93 16.85 30 23421 22367 63443204

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pancreatitis 1783.45 18.38 678 16251 38213 34901789
Blood glucose increased 1127.36 18.38 577 16352 66141 34873861
Injection site nodule 957.95 18.38 210 16719 1473 34938529
Weight decreased 766.43 18.38 651 16278 175650 34764352
Pancreatitis acute 472.26 18.38 243 16686 27898 34912104
Device leakage 359.60 18.38 131 16798 6444 34933558
Injection site haemorrhage 353.18 18.38 144 16785 9624 34930378
Injection site mass 307.36 18.38 117 16812 6509 34933493
Pancreatic carcinoma 304.03 18.38 126 16803 8775 34931227
Nausea 287.49 18.38 554 16375 339354 34600648
Incorrect dose administered by device 266.67 18.38 77 16852 1781 34938221
Blood glucose decreased 259.10 18.38 127 16802 13110 34926892
Injection site pain 243.18 18.38 179 16750 38826 34901176
Glycosylated haemoglobin increased 234.37 18.38 113 16816 11247 34928755
Injection site extravasation 231.81 18.38 77 16852 2865 34937137
Wrong technique in device usage process 187.70 18.38 56 16873 1456 34938546
Blood glucose abnormal 159.51 18.38 71 16858 5881 34934121
Injection site pruritus 145.62 18.38 70 16859 6913 34933089
Device delivery system issue 144.27 18.38 36 16893 465 34939537
Cholelithiasis 138.35 18.38 100 16829 21048 34918954
Intentional device misuse 135.90 18.38 29 16900 175 34939827
Pancreatic carcinoma metastatic 129.43 18.38 50 16879 2890 34937112
Device malfunction 121.90 18.38 71 16858 10350 34929652
Lipase increased 120.43 18.38 68 16861 9348 34930654
Hypoglycaemia 102.13 18.38 129 16800 54511 34885491
Product quality issue 98.93 18.38 75 16854 16960 34923042
Needle issue 93.96 18.38 50 16879 6115 34933887
Injection site erythema 92.33 18.38 70 16859 15829 34924173
Underdose 85.20 18.38 63 16866 13717 34926285
Adenocarcinoma pancreas 84.95 18.38 30 16899 1344 34938658
Diabetes mellitus inadequate control 84.25 18.38 62 16867 13402 34926600
Drug delivery system issue 83.18 18.38 14 16915 14 34939988
Vomiting 79.84 18.38 282 16647 247339 34692663
Injection site urticaria 76.38 18.38 31 16898 2041 34937961
Device issue 72.65 18.38 50 16879 9727 34930275
Decreased appetite 72.23 18.38 210 16719 166182 34773820
Toxicity to various agents 71.87 18.38 7 16922 200355 34739647
Injection site bruising 70.81 18.38 47 16882 8616 34931386
Blood glucose fluctuation 70.80 18.38 36 16893 4008 34935994
Drug dose omission by device 70.72 18.38 30 16899 2209 34937793
Incorrect dose administered 69.94 18.38 92 16837 40423 34899579
Pancreatitis chronic 64.13 18.38 28 16901 2212 34937790
Device use issue 63.24 18.38 20 16909 634 34939368
Pancreatitis necrotising 55.53 18.38 27 16902 2731 34937271
Death 53.34 18.38 69 16860 397980 34542022
Injection site rash 53.11 18.38 30 16899 4123 34935879
Pancreaticoduodenectomy 52.64 18.38 11 16918 59 34939943
Neutropenia 52.38 18.38 7 16922 156771 34783231
Pyrexia 51.92 18.38 51 16878 332962 34607040
Metastases to liver 49.86 18.38 46 16883 13617 34926385
Diabetic ketoacidosis 49.57 18.38 52 16877 17980 34922022
Cholecystectomy 48.65 18.38 25 16904 2845 34937157
Injection site swelling 48.38 18.38 42 16887 11485 34928517
Injection site abscess 46.69 18.38 17 16912 832 34939170
Injection site irritation 46.62 18.38 19 16910 1264 34938738
Thrombocytopenia 45.56 18.38 10 16919 156237 34783765
Pneumonia 45.38 18.38 66 16863 362561 34577441
Injection site reaction 43.95 18.38 42 16887 12991 34927011
Product use in unapproved indication 42.37 18.38 4 16925 117495 34822507
Amylase increased 40.78 18.38 29 16900 5939 34934063
Nodule 39.52 18.38 30 16899 6789 34933213
Anaemia 38.35 18.38 34 16895 233301 34706701
Disease progression 38.12 18.38 4 16925 108073 34831929
Drug abuse 36.73 18.38 3 16926 99093 34840909
Blood triglycerides increased 35.68 18.38 39 16890 14120 34925882
Hepatic steatosis 35.29 18.38 44 16885 18318 34921684
Renal failure 34.69 18.38 140 16789 130417 34809585
Platelet count decreased 34.21 18.38 8 16921 119709 34820293
Impaired gastric emptying 33.82 18.38 21 16908 3432 34936570
Injection site induration 32.15 18.38 19 16910 2841 34937161
Injury associated with device 32.02 18.38 14 16915 1109 34938893
Malignant neoplasm progression 31.72 18.38 3 16926 88043 34851959
Circumstance or information capable of leading to medication error 31.61 18.38 16 16913 1763 34938239
Hyperglycaemia 31.30 18.38 63 16866 39417 34900585
General physical health deterioration 30.46 18.38 12 16917 128257 34811745
White blood cell count decreased 30.15 18.38 5 16924 95440 34844562
Pancytopenia 30.03 18.38 5 16924 95152 34844850
Pancreatic neuroendocrine tumour 29.45 18.38 9 16920 254 34939748
Injection site injury 29.42 18.38 9 16920 255 34939747
Abdominal pain upper 28.80 18.38 88 16841 71402 34868600
Pancreatic neoplasm 28.12 18.38 12 16917 896 34939106
Bile duct stent insertion 28.08 18.38 7 16922 90 34939912
Fatigue 27.61 18.38 90 16839 370563 34569439
Pancreatitis haemorrhagic 27.13 18.38 9 16920 333 34939669
Pancreatic stent placement 27.05 18.38 5 16924 12 34939990
COVID-19 27.01 18.38 3 16926 77547 34862455
Device defective 26.66 18.38 11 16918 755 34939247
Drug interaction 26.39 18.38 43 16886 225903 34714099
Injection site cellulitis 25.99 18.38 10 16919 571 34939431
Biliary dyskinesia 25.72 18.38 6 16923 57 34939945
Therapeutic product effect decreased 24.68 18.38 53 16876 34690 34905312
Abdominal pain 24.48 18.38 149 16780 163469 34776533
Early satiety 24.16 18.38 10 16919 692 34939310
Eructation 23.49 18.38 19 16910 4712 34935290
Pancreatic cyst 23.04 18.38 10 16919 778 34939224
Condition aggravated 22.98 18.38 36 16893 192160 34747842
Pancreatic pseudocyst 22.35 18.38 10 16919 837 34939165
Drug delivery system malfunction 22.22 18.38 8 16921 379 34939623
Hyperlipidaemia 22.02 18.38 31 16898 14498 34925504
Feeling jittery 21.86 18.38 17 16912 3986 34936016
Injection site discomfort 21.59 18.38 12 16917 1598 34938404
Distributive shock 21.47 18.38 11 16918 1243 34938759
Pancreatic enzymes increased 21.47 18.38 9 16920 643 34939359
Hepatic cancer 21.21 18.38 23 16906 8252 34931750
Insulin-requiring type 2 diabetes mellitus 20.52 18.38 6 16923 145 34939857
Leukopenia 20.51 18.38 3 16926 62853 34877149
Injection site haematoma 20.44 18.38 12 16917 1773 34938229
Diverticulum 20.30 18.38 21 16908 7138 34932864
Dehydration 19.83 18.38 119 16810 129850 34810152
Injection site scar 19.81 18.38 7 16922 314 34939688
Hypoglycaemic unconsciousness 19.72 18.38 9 16920 789 34939213
Pancreatic duct dilatation 19.53 18.38 5 16924 72 34939930
Interstitial lung disease 19.37 18.38 4 16925 65278 34874724
Haemoglobin decreased 19.32 18.38 18 16911 120754 34819248
Diabetic neuropathy 19.05 18.38 16 16913 4181 34935821
Cholecystitis chronic 18.78 18.38 9 16920 881 34939121
Hunger 18.62 18.38 11 16918 1643 34938359
Glycosylated haemoglobin decreased 18.53 18.38 7 16922 380 34939622
Injection site indentation 18.49 18.38 4 16925 26 34939976

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Blood glucose increased 2091.43 17.60 895 22435 114080 79606978
Pancreatitis 1583.55 17.60 634 22696 67941 79653117
Injection site nodule 1085.95 17.60 246 23084 3534 79717524
Weight decreased 999.46 17.60 825 22505 354373 79366685
Nausea 630.75 17.60 1050 22280 956146 78764912
Blood glucose decreased 513.47 17.60 216 23114 26018 79695040
Injection site haemorrhage 442.51 17.60 198 23132 27672 79693386
Device leakage 378.51 17.60 136 23194 10720 79710338
Incorrect dose administered by device 367.17 17.60 110 23220 4879 79716179
Pancreatitis acute 361.13 17.60 208 23122 49396 79671662
Glycosylated haemoglobin increased 345.05 17.60 149 23181 19111 79701947
Injection site pruritus 333.88 17.60 187 23143 42096 79678962
Injection site mass 315.87 17.60 142 23188 20042 79701016
Injection site pain 271.45 17.60 256 23074 129582 79591476
Wrong technique in device usage process 254.52 17.60 79 23251 3949 79717109
Device delivery system issue 250.52 17.60 55 23275 676 79720382
Hypoglycaemia 227.10 17.60 208 23122 101386 79619672
Vomiting 221.59 17.60 553 22777 665275 79055783
Injection site extravasation 217.48 17.60 88 23242 9581 79711477
Decreased appetite 206.02 17.60 363 22967 342055 79379003
Injection site urticaria 199.88 17.60 90 23240 12736 79708322
Pancreatic carcinoma 191.86 17.60 89 23241 13488 79707570
Blood glucose abnormal 186.76 17.60 81 23249 10485 79710573
Injection site erythema 164.81 17.60 155 23175 78042 79643016
Injection site bruising 148.18 17.60 111 23219 40891 79680167
Product quality issue 148.06 17.60 103 23227 33837 79687221
Device malfunction 145.54 17.60 86 23244 21362 79699696
Lipase increased 144.12 17.60 78 23252 16388 79704670
Incorrect dose administered 142.85 17.60 142 23188 76488 79644570
Blood glucose fluctuation 140.65 17.60 58 23272 6624 79714434
Injection site rash 121.84 17.60 72 23258 17882 79703176
Injection site irritation 111.79 17.60 42 23288 3748 79717310
Diabetic ketoacidosis 109.31 17.60 86 23244 34036 79687022
Needle issue 103.61 17.60 58 23272 13010 79708048
Diabetes mellitus inadequate control 97.39 17.60 70 23260 24194 79696864
Device use issue 86.31 17.60 32 23298 2752 79718306
Underdose 86.16 17.60 74 23256 33077 79687981
Toxicity to various agents 79.12 17.60 14 23316 421526 79299532
Drug delivery system issue 78.63 17.60 15 23315 85 79720973
Early satiety 77.53 17.60 25 23305 1414 79719644
Intentional device misuse 74.07 17.60 21 23309 764 79720294
Injection site swelling 71.04 17.60 78 23252 47054 79674004
Cholelithiasis 70.60 17.60 82 23248 52582 79668476
Eructation 69.47 17.60 42 23288 10867 79710191
Amylase increased 65.87 17.60 41 23289 11168 79709890
Acute kidney injury 64.97 17.60 312 23018 519092 79201966
Pyrexia 64.80 17.60 62 23268 678647 79042411
Drug dose omission by device 64.32 17.60 33 23297 6217 79714841
Device issue 63.40 17.60 57 23273 27051 79694007
Urticaria 63.38 17.60 156 23174 185045 79536013
Injury associated with device 59.09 17.60 26 23304 3480 79717578
Pneumonia 57.72 17.60 65 23265 660181 79060877
Neutropenia 55.17 17.60 9 23321 287701 79433357
Infusion related reaction 55.11 17.60 3 23327 230234 79490824
Hyperglycaemia 53.42 17.60 83 23247 70252 79650806
Febrile neutropenia 52.36 17.60 4 23326 230995 79490063
Lactic acidosis 52.01 17.60 82 23248 70277 79650781
Impaired gastric emptying 51.27 17.60 34 23296 10319 79710739
Pancreatic carcinoma metastatic 48.08 17.60 23 23307 3730 79717328
Thrombocytopenia 45.21 17.60 11 23319 265248 79455810
Feeling jittery 44.67 17.60 34 23296 12807 79708251
Abdominal distension 44.35 17.60 104 23226 119546 79601512
Product use in unapproved indication 43.42 17.60 10 23320 250349 79470709
Injection site induration 43.27 17.60 30 23300 9789 79711269
Dehydration 43.23 17.60 165 23165 248022 79473036
Device defective 41.54 17.60 17 23313 1903 79719155
Pancreatitis necrotising 41.27 17.60 21 23309 3887 79717171
Circumstance or information capable of leading to medication error 41.07 17.60 21 23309 3927 79717131
Drug intolerance 39.44 17.60 14 23316 264105 79456953
Treatment failure 38.49 17.60 3 23327 170483 79550575
White blood cell count decreased 38.14 17.60 5 23325 188283 79532775
Injection site inflammation 38.06 17.60 20 23310 3956 79717102
General physical health deterioration 37.17 17.60 17 23313 275221 79445837
Injection site abscess 37.12 17.60 15 23315 1625 79719433
Injection site indentation 36.75 17.60 9 23321 183 79720875
Joint swelling 35.73 17.60 20 23310 288626 79432432
Platelet count decreased 35.33 17.60 7 23323 194657 79526401
Disease progression 34.81 17.60 6 23324 184356 79536702
Product dose omission issue 34.75 17.60 154 23176 247383 79473675
Adenocarcinoma pancreas 34.01 17.60 15 23315 2018 79719040
Increased appetite 33.71 17.60 28 23302 11950 79709108
Injection site cellulitis 33.40 17.60 14 23316 1664 79719394
Death 33.07 17.60 73 23257 566441 79154617
Anaemia 32.48 17.60 50 23280 444965 79276093
Device failure 32.06 17.60 21 23309 6240 79714818
Blood triglycerides increased 32.00 17.60 35 23295 21005 79700053
Pain 31.79 17.60 103 23227 703699 79017359
Rheumatoid arthritis 31.20 17.60 11 23319 208459 79512599
Abdominal pain 30.69 17.60 207 23123 389362 79331696
Feeling abnormal 29.49 17.60 108 23222 159091 79561967
Malignant neoplasm progression 29.06 17.60 3 23327 135987 79585071
Musculoskeletal stiffness 28.39 17.60 8 23322 175000 79546058
Injection site injury 28.32 17.60 10 23320 747 79720311
Ketoacidosis 27.77 17.60 21 23309 7833 79713225
Hyponatraemia 27.28 17.60 9 23321 177839 79543219
Medication error 25.79 17.60 60 23270 68582 79652476
Injection site reaction 25.26 17.60 52 23278 54733 79666325
Glycosylated haemoglobin decreased 25.23 17.60 9 23321 693 79720365
Peripheral swelling 25.22 17.60 25 23305 269592 79451466
Renal failure 25.21 17.60 121 23209 200847 79520211
Stomatitis 25.16 17.60 6 23324 146751 79574307
Cough 25.07 17.60 43 23287 366746 79354312
Hunger 24.90 17.60 17 23313 5411 79715647
Injection site haematoma 24.26 17.60 16 23314 4811 79716247
Wound 23.73 17.60 3 23327 116176 79604882
Injection site infection 23.69 17.60 12 23318 2200 79718858
Injection site discomfort 23.27 17.60 16 23314 5150 79715908
Intentional product use issue 22.80 17.60 8 23322 152104 79568954
Lower respiratory tract infection 22.71 17.60 5 23325 129215 79591843
Oxygen saturation decreased 22.67 17.60 5 23325 129042 79592016
Coronary artery occlusion 22.47 17.60 25 23305 15290 79705768
Drug ineffective 22.20 17.60 206 23124 1080707 78640351
Therapeutic product effect incomplete 22.02 17.60 7 23323 141638 79579420
Infection 21.93 17.60 23 23307 241689 79479369
Pancreatitis chronic 21.86 17.60 14 23316 4005 79717053
Therapeutic response unexpected 21.76 17.60 28 23302 19918 79701140
Arthralgia 21.62 17.60 90 23240 571713 79149345
Nodule 21.59 17.60 30 23300 22964 79698094
Fatigue 21.39 17.60 172 23158 929555 78791503
Hyperhidrosis 21.05 17.60 94 23236 151398 79569660
Arthropathy 20.87 17.60 13 23317 177098 79543960
COVID-19 20.87 17.60 10 23320 157664 79563394
C-reactive protein increased 20.74 17.60 6 23324 129021 79592037
Confusional state 20.19 17.60 39 23291 317958 79403100
Distributive shock 18.81 17.60 11 23319 2676 79718382
Hepatic steatosis 18.80 17.60 37 23293 37701 79683357
Dyspepsia 18.68 17.60 72 23258 108615 79612443
Interstitial lung disease 18.53 17.60 5 23325 112595 79608463
Cardiac arrest 18.46 17.60 14 23316 172082 79548976
Seizure 18.24 17.60 17 23313 188817 79532241
Therapeutic product effect decreased 17.96 17.60 95 23235 163768 79557290
Drug delivery system malfunction 17.76 17.60 7 23323 710 79720348
Leukopenia 17.68 17.60 6 23324 116507 79604551

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A10BJ01 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Glucagon-like peptide-1 (GLP-1) analogues
FDA CS M0160181 Glucagon-Like Peptide 1
FDA MoA N0000020058 Glucagon-like Peptide-1 (GLP-1) Agonists
MeSH PA D019440 Anti-Obesity Agents
MeSH PA D006728 Hormones
MeSH PA D007004 Hypoglycemic Agents
MeSH PA D054795 Incretins
FDA EPC N0000178480 GLP-1 Receptor Agonist
CHEBI has role CHEBI:35526 antidiabetic
CHEBI has role CHEBI:64088 incretin mimetics
CHEBI has role CHEBI:71196 GLP-1 receptor agonist

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Type 2 Diabetes Mellitus Treatment Adjunct indication
Alcoholism contraindication 7200002
Acute vomiting contraindication 23971007
Dehydration contraindication 34095006
Hypertensive disorder contraindication 38341003 DOID:10763
Acute nephropathy contraindication 58574008
Transplant of kidney contraindication 70536003
Pancreatitis contraindication 75694006 DOID:4989
Chronic renal failure syndrome contraindication 90688005
Impaired renal function disorder contraindication 197663003
Gastroparesis contraindication 235675006
Hypoglycemic disorder contraindication 237630007
Calculus in biliary tract contraindication 266474003
Severe diarrhea contraindication 409587002




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.15 acidic
pKa2 3.62 acidic
pKa3 3.86 acidic
pKa4 4.07 acidic
pKa5 4.31 acidic
pKa6 4.6 acidic
pKa7 12.09 acidic
pKa8 12.31 acidic
pKa9 12.61 acidic
pKa10 12.68 acidic
pKa11 12.87 acidic
pKa12 12.92 acidic
pKa13 12.99 acidic
pKa14 13.18 acidic
pKa15 13.2 acidic
pKa16 13.29 acidic
pKa17 13.3 acidic
pKa18 13.4 acidic
pKa19 13.5 acidic
pKa20 13.51 acidic
pKa21 13.52 acidic
pKa22 13.64 acidic
pKa23 13.68 acidic
pKa24 13.77 acidic
pKa25 13.82 acidic
pKa26 13.86 acidic
pKa27 11.25 Basic
pKa28 10.81 Basic
pKa29 10.31 Basic
pKa30 7.86 Basic
pKa31 5.98 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9238076 April 15, 2024 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH BASAL INSULIN OR BASAL INSULIN PLUS METFORMIN
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9238076 April 15, 2024 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9238076 April 15, 2024 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, A THIAZOLIDINEDIONE, OR COMBINATION OF ANY TWO OF THESE THERAPIES
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9238076 April 15, 2024 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH INSULIN ALONE OR INSULIN PLUS ONE OTHER ORAL ANTIDIABETIC MEDICATION
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9238076 April 15, 2024 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR SULFONYLUREA
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9238076 April 15, 2024 IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE TO PROVIDE A RELEASE PROFILE HAVING A RATIO OF C-MAX TO C-AVG OF ABOUT 3 OR LESS
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9238076 April 15, 2024 IMPROVING GLYCEMIC CONTROL IN PATIENTS 10 YEARS OF AGE AND OLDER WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A SUSTAINED-RELEASE EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9238076 April 15, 2024 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH BASAL INSULIN OR BASAL INSULIN PLUS METFORMIN
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9238076 April 15, 2024 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9238076 April 15, 2024 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, A THIAZOLIDINEDIONE, OR COMBINATION OF ANY TWO OF THESE THERAPIES
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9238076 April 15, 2024 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH INSULIN ALONE OR INSULIN PLUS ONE OTHER ORAL ANTIDIABETIC MEDICATION
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9238076 April 15, 2024 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR SULFONYLUREA
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9238076 April 15, 2024 IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE TO PROVIDE A RELEASE PROFILE HAVING A RATIO OF C-MAX TO C-AVG OF ABOUT 3 OR LESS
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9238076 April 15, 2024 IMPROVING GLYCEMIC CONTROL IN PATIENTS 10 YEARS OF AGE AND OLDER WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A SUSTAINED-RELEASE EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9238076 April 15, 2024 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH BASAL INSULIN OR BASAL INSULIN PLUS METFORMIN
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9238076 April 15, 2024 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9238076 April 15, 2024 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AS ADD-ON TO METFORMIN
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9238076 April 15, 2024 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, A THIAZOLIDINEDIONE, OR COMBINATION OF ANY TWO OF THESE THERAPIES
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9238076 April 15, 2024 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH INSULIN ALONE OR INSULIN PLUS ONE OTHER ORAL ANTIDIABETIC MEDICATION
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9238076 April 15, 2024 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR SULFONYLUREA
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9238076 April 15, 2024 IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE TO PROVIDE A RELEASE PROFILE HAVING A RATIO OF C-MAX TO C-AVG OF ABOUT 3 OR LESS
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9238076 April 15, 2024 IMPROVING GLYCEMIC CONTROL IN PATIENTS 10 YEARS OF AGE AND OLDER WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A SUSTAINED-RELEASE EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 7612176 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH BASAL INSULIN OR BASAL INSULIN PLUS METFORMIN
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 7612176 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 7612176 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, A THIAZOLIDINEDIONE, OR COMBINATION OF ANY TWO OF THESE THERAPIES
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 7612176 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH INSULIN ALONE OR INSULIN PLUS ONE OTHER ORAL ANTIDIABETIC MEDICATION
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 7612176 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR SULFONYLUREA
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 7612176 April 13, 2025 IMPROVING GLYCEMIC CONTROL IN PATIENTS 10 YEARS OF AGE AND OLDER WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A SUSTAINED-RELEASE EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8431685 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH BASAL INSULIN OR BASAL INSULIN PLUS METFORMIN
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8431685 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8431685 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, A THIAZOLIDINEDIONE, OR COMBINATION OF ANY TWO OF THESE THERAPIES
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8431685 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH INSULIN ALONE OR INSULIN PLUS ONE OTHER ORAL ANTIDIABETIC MEDICATION
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8431685 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR SULFONYLUREA
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8431685 April 13, 2025 IMPROVING GLYCEMIC CONTROL IN PATIENTS 10 YEARS OF AGE AND OLDER WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A SUSTAINED-RELEASE EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8461105 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH BASAL INSULIN OR BASAL INSULIN PLUS METFORMIN
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8461105 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8461105 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, A THIAZOLIDINEDIONE, OR COMBINATION OF ANY TWO OF THESE THERAPIES
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8461105 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH INSULIN ALONE OR INSULIN PLUS ONE OTHER ORAL ANTIDIABETIC MEDICATION
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8461105 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR SULFONYLUREA
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8461105 April 13, 2025 IMPROVING GLYCEMIC CONTROL IN PATIENTS 10 YEARS OF AGE AND OLDER WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A SUSTAINED-RELEASE EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 7612176 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH BASAL INSULIN OR BASAL INSULIN PLUS METFORMIN
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 7612176 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 7612176 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, A THIAZOLIDINEDIONE, OR COMBINATION OF ANY TWO OF THESE THERAPIES
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 7612176 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH INSULIN ALONE OR INSULIN PLUS ONE OTHER ORAL ANTIDIABETIC MEDICATION
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 7612176 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR SULFONYLUREA
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 7612176 April 13, 2025 IMPROVING GLYCEMIC CONTROL IN PATIENTS 10 YEARS OF AGE AND OLDER WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A SUSTAINED-RELEASE EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8431685 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH BASAL INSULIN OR BASAL INSULIN PLUS METFORMIN
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8431685 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8431685 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, A THIAZOLIDINEDIONE, OR COMBINATION OF ANY TWO OF THESE THERAPIES
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8431685 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH INSULIN ALONE OR INSULIN PLUS ONE OTHER ORAL ANTIDIABETIC MEDICATION
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8431685 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR SULFONYLUREA
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8431685 April 13, 2025 IMPROVING GLYCEMIC CONTROL IN PATIENTS 10 YEARS OF AGE AND OLDER WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A SUSTAINED-RELEASE EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8461105 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH BASAL INSULIN OR BASAL INSULIN PLUS METFORMIN
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8461105 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8461105 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, A THIAZOLIDINEDIONE, OR COMBINATION OF ANY TWO OF THESE THERAPIES
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8461105 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH INSULIN ALONE OR INSULIN PLUS ONE OTHER ORAL ANTIDIABETIC MEDICATION
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8461105 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR SULFONYLUREA
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8461105 April 13, 2025 IMPROVING GLYCEMIC CONTROL IN PATIENTS 10 YEARS OF AGE AND OLDER WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A SUSTAINED-RELEASE EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 7612176 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH BASAL INSULIN OR BASAL INSULIN PLUS METFORMIN
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 7612176 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, A THIAZOLIDINEDIONE, OR COMBINATION OF ANY TWO OF THESE THERAPIES
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 7612176 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH INSULIN ALONE OR INSULIN PLUS ONE OTHER ORAL ANTIDIABETIC MEDICATION
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 7612176 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR SULFONYLUREA
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 7612176 April 13, 2025 IMPROVING GLYCEMIC CONTROL IN PATIENTS 10 YEARS OF AGE AND OLDER WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A SUSTAINED-RELEASE EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8431685 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH BASAL INSULIN OR BASAL INSULIN PLUS METFORMIN
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8431685 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8431685 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AS ADD-ON TO METFORMIN
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8431685 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, A THIAZOLIDINEDIONE, OR COMBINATION OF ANY TWO OF THESE THERAPIES
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8431685 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH INSULIN ALONE OR INSULIN PLUS ONE OTHER ORAL ANTIDIABETIC MEDICATION
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8431685 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR SULFONYLUREA
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8431685 April 13, 2025 IMPROVING GLYCEMIC CONTROL IN PATIENTS 10 YEARS OF AGE AND OLDER WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A SUSTAINED-RELEASE EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8461105 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH BASAL INSULIN OR BASAL INSULIN PLUS METFORMIN
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8461105 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8461105 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AS ADD-ON TO METFORMIN
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8461105 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, A THIAZOLIDINEDIONE, OR COMBINATION OF ANY TWO OF THESE THERAPIES
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8461105 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH INSULIN ALONE OR INSULIN PLUS ONE OTHER ORAL ANTIDIABETIC MEDICATION
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8461105 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR SULFONYLUREA
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8461105 April 13, 2025 IMPROVING GLYCEMIC CONTROL IN PATIENTS 10 YEARS OF AGE AND OLDER WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A SUSTAINED-RELEASE EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 7456254 June 30, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH BASAL INSULIN OR BASAL INSULIN PLUS METFORMIN
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 7456254 June 30, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 7456254 June 30, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, A THIAZOLIDINEDIONE, OR COMBINATION OF ANY TWO OF THESE THERAPIES
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 7456254 June 30, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH INSULIN ALONE OR INSULIN PLUS ONE OTHER ORAL ANTIDIABETIC MEDICATION
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 7456254 June 30, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR SULFONYLUREA
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 7456254 June 30, 2025 IMPROVING GLYCEMIC CONTROL IN PATIENTS 10 YEARS OF AGE AND OLDER WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A SUSTAINED-RELEASE EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 7456254 June 30, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH BASAL INSULIN OR BASAL INSULIN PLUS METFORMIN
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 7456254 June 30, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 7456254 June 30, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, A THIAZOLIDINEDIONE, OR COMBINATION OF ANY TWO OF THESE THERAPIES
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 7456254 June 30, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH INSULIN ALONE OR INSULIN PLUS ONE OTHER ORAL ANTIDIABETIC MEDICATION
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 7456254 June 30, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR SULFONYLUREA
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 7456254 June 30, 2025 IMPROVING GLYCEMIC CONTROL IN PATIENTS 10 YEARS OF AGE AND OLDER WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A SUSTAINED-RELEASE EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 7456254 June 30, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH BASAL INSULIN OR BASAL INSULIN PLUS METFORMIN
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 7456254 June 30, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 7456254 June 30, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, A THIAZOLIDINEDIONE, OR COMBINATION OF ANY TWO OF THESE THERAPIES
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 7456254 June 30, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH INSULIN ALONE OR INSULIN PLUS ONE OTHER ORAL ANTIDIABETIC MEDICATION
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 7456254 June 30, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR SULFONYLUREA
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 7456254 June 30, 2025 IMPROVING GLYCEMIC CONTROL IN PATIENTS 10 YEARS OF AGE AND OLDER WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A SUSTAINED-RELEASE EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 6515117 Oct. 4, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 6515117 Oct. 4, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 6515117 Oct. 4, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH BASAL INSULIN OR BASAL INSULIN PLUS METFORMIN
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, A THIAZOLIDINEDIONE, OR COMBINATION OF ANY TWO OF THESE THERAPIES
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH INSULIN ALONE OR INSULIN PLUS ONE OTHER ORAL ANTIDIABETIC MEDICATION
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR SULFONYLUREA
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 IMPROVING GLYCEMIC CONTROL IN PATIENTS 10 YEARS OF AGE AND OLDER WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A SUSTAINED-RELEASE EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 REDUCING BODY WEIGHT IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 REDUCING FASTING PLASMA GLUCOSE IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 REDUCING HBA1C IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8906851 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH BASAL INSULIN OR BASAL INSULIN PLUS METFORMIN
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8906851 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8906851 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, A THIAZOLIDINEDIONE, OR COMBINATION OF ANY TWO OF THESE THERAPIES
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8906851 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH INSULIN ALONE OR INSULIN PLUS ONE OTHER ORAL ANTIDIABETIC MEDICATION
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8906851 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR SULFONYLUREA
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8906851 Aug. 18, 2026 IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8906851 Aug. 18, 2026 IMPROVING GLYCEMIC CONTROL IN PATIENTS 10 YEARS OF AGE AND OLDER WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A SUSTAINED-RELEASE EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH BASAL INSULIN OR BASAL INSULIN PLUS METFORMIN
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, A THIAZOLIDINEDIONE, OR COMBINATION OF ANY TWO OF THESE THERAPIES
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH INSULIN ALONE OR INSULIN PLUS ONE OTHER ORAL ANTIDIABETIC MEDICATION
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR SULFONYLUREA
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 IMPROVING GLYCEMIC CONTROL IN PATIENTS 10 YEARS OF AGE AND OLDER WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A SUSTAINED-RELEASE EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 REDUCING BODY WEIGHT IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 REDUCING FASTING PLASMA GLUCOSE IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 REDUCING HBA1C IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH BASAL INSULIN OR BASAL INSULIN PLUS METFORMIN
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, A THIAZOLIDINEDIONE, OR COMBINATION OF ANY TWO OF THESE THERAPIES
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH INSULIN ALONE OR INSULIN PLUS ONE OTHER ORAL ANTIDIABETIC MEDICATION
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR SULFONYLUREA
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 IMPROVING GLYCEMIC CONTROL IN PATIENTS 10 YEARS OF AGE AND OLDER WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A SUSTAINED-RELEASE EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 REDUCING BODY WEIGHT IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 REDUCING FASTING PLASMA GLUCOSE IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 REDUCING HBA1C IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8906851 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH BASAL INSULIN OR BASAL INSULIN PLUS METFORMIN
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8906851 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8906851 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, A THIAZOLIDINEDIONE, OR COMBINATION OF ANY TWO OF THESE THERAPIES
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8906851 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH INSULIN ALONE OR INSULIN PLUS ONE OTHER ORAL ANTIDIABETIC MEDICATION
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8906851 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR SULFONYLUREA
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8906851 Aug. 18, 2026 IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8906851 Aug. 18, 2026 IMPROVING GLYCEMIC CONTROL IN PATIENTS 10 YEARS OF AGE AND OLDER WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A SUSTAINED-RELEASE EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH BASAL INSULIN OR BASAL INSULIN PLUS METFORMIN
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, A THIAZOLIDINEDIONE, OR COMBINATION OF ANY TWO OF THESE THERAPIES
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH INSULIN ALONE OR INSULIN PLUS ONE OTHER ORAL ANTIDIABETIC MEDICATION
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR SULFONYLUREA
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 IMPROVING GLYCEMIC CONTROL IN PATIENTS 10 YEARS OF AGE AND OLDER WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A SUSTAINED-RELEASE EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 REDUCING BODY WEIGHT IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 REDUCING FASTING PLASMA GLUCOSE IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 REDUCING HBA1C IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH BASAL INSULIN OR BASAL INSULIN PLUS METFORMIN
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, A THIAZOLIDINEDIONE, OR COMBINATION OF ANY TWO OF THESE THERAPIES
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH INSULIN ALONE OR INSULIN PLUS ONE OTHER ORAL ANTIDIABETIC MEDICATION
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR SULFONYLUREA
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 IMPROVING GLYCEMIC CONTROL IN PATIENTS 10 YEARS OF AGE AND OLDER WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A SUSTAINED-RELEASE EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 REDUCING BODY WEIGHT IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 REDUCING FASTING PLASMA GLUCOSE IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 REDUCING HBA1C IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8906851 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH BASAL INSULIN OR BASAL INSULIN PLUS METFORMIN
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8906851 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8906851 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AS ADD-ON TO METFORMIN
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8906851 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, A THIAZOLIDINEDIONE, OR COMBINATION OF ANY TWO OF THESE THERAPIES
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8906851 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH INSULIN ALONE OR INSULIN PLUS ONE OTHER ORAL ANTIDIABETIC MEDICATION
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8906851 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR SULFONYLUREA
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8906851 Aug. 18, 2026 IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8906851 Aug. 18, 2026 IMPROVING GLYCEMIC CONTROL IN PATIENTS 10 YEARS OF AGE AND OLDER WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A SUSTAINED-RELEASE EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH BASAL INSULIN OR BASAL INSULIN PLUS METFORMIN
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AS ADD-ON TO METFORMIN
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, A THIAZOLIDINEDIONE, OR COMBINATION OF ANY TWO OF THESE THERAPIES
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH INSULIN ALONE OR INSULIN PLUS ONE OTHER ORAL ANTIDIABETIC MEDICATION
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR SULFONYLUREA
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 IMPROVING GLYCEMIC CONTROL IN PATIENTS 10 YEARS OF AGE AND OLDER WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A SUSTAINED-RELEASE EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 REDUCING BODY WEIGHT IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 REDUCING FASTING PLASMA GLUCOSE IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 REDUCING HBA1C IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8501698 June 20, 2027 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8501698 June 20, 2027 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8501698 June 20, 2027 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8361972 March 21, 2028 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8361972 March 21, 2028 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8361972 March 21, 2028 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8895033 Oct. 4, 2030 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH BASAL INSULIN OR BASAL INSULIN PLUS METFORMIN
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8895033 Oct. 4, 2030 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AS ADD-ON TO METFORMIN
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8895033 Oct. 4, 2030 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, A THIAZOLIDINEDIONE, OR COMBINATION OF ANY TWO OF THESE THERAPIES
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8895033 Oct. 4, 2030 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH INSULIN ALONE OR INSULIN PLUS ONE OTHER ORAL ANTIDIABETIC MEDICATION
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8895033 Oct. 4, 2030 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR SULFONYLUREA
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8895033 Oct. 4, 2030 DELAYING GASTRIC EMPTYING IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A PRE-MIXED EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8895033 Oct. 4, 2030 IMPROVING GLYCEMIC CONTROL IN PATIENTS 10 YEARS OF AGE AND OLDER WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A SUSTAINED-RELEASE EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8895033 Oct. 4, 2030 STIMULATING INSULIN RELEASE IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A PRE-MIXED EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS Aug. 15, 2023 PEDIATRIC EXCLUSIVITY
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS Aug. 15, 2023 PEDIATRIC EXCLUSIVITY
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS Aug. 15, 2023 PEDIATRIC EXCLUSIVITY
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS July 22, 2024 NEW PATIENT POPULATION
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS July 22, 2024 NEW PATIENT POPULATION
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS July 22, 2024 NEW PATIENT POPULATION
300MCG/1.2ML (250MCG/ML) BYETTA ASTRAZENECA AB N021773 April 28, 2005 RX INJECTABLE SUBCUTANEOUS Nov. 4, 2024 INFORMATION ADDED TO SECTION 8.4 OF THE LABELING TO DESCRIBE THE RESULTS FROM PEDIATRIC STUDIES
600MCG/2.4ML (250MCG/ML) BYETTA ASTRAZENECA AB N021773 April 28, 2005 RX INJECTABLE SUBCUTANEOUS Nov. 4, 2024 INFORMATION ADDED TO SECTION 8.4 OF THE LABELING TO DESCRIBE THE RESULTS FROM PEDIATRIC STUDIES
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS Jan. 22, 2025 PEDIATRIC EXCLUSIVITY
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS Jan. 22, 2025 PEDIATRIC EXCLUSIVITY
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS Jan. 22, 2025 PEDIATRIC EXCLUSIVITY

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Glucagon-like peptide 1 receptor GPCR AGONIST IC50 9.18 CHEMBL CHEMBL
Glucagon-like peptide 1 receptor GPCR IC50 9.85 CHEMBL

External reference:

IDSource
4024921 VUID
N0000171592 NUI
D04121 KEGG_DRUG
4024921 VANDF
C0167117 UMLSCUI
CHEBI:64073 CHEBI
CHEMBL414357 ChEMBL_ID
D000077270 MESH_DESCRIPTOR_UI
DB01276 DRUGBANK_ID
8219 INN_ID
9P1872D4OL UNII
45588096 PUBCHEM_CID
1242964 RXNORM
184698 MMSL
19812 MMSL
d05529 MMSL
010772 NDDF
416859008 SNOMEDCT_US
417734003 SNOMEDCT_US
CHEMBL1210015 ChEMBL_ID
1135 IUPHAR_LIGAND_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Byetta HUMAN PRESCRIPTION DRUG LABEL 1 0310-6512 INJECTION 250 ug SUBCUTANEOUS NDA 29 sections
Byetta HUMAN PRESCRIPTION DRUG LABEL 1 0310-6512 INJECTION 250 ug SUBCUTANEOUS NDA 29 sections
Byetta HUMAN PRESCRIPTION DRUG LABEL 1 0310-6512 INJECTION 250 ug SUBCUTANEOUS NDA 29 sections
Byetta HUMAN PRESCRIPTION DRUG LABEL 1 0310-6524 INJECTION 250 ug SUBCUTANEOUS NDA 29 sections
Byetta HUMAN PRESCRIPTION DRUG LABEL 1 0310-6524 INJECTION 250 ug SUBCUTANEOUS NDA 29 sections
Byetta HUMAN PRESCRIPTION DRUG LABEL 1 0310-6524 INJECTION 250 ug SUBCUTANEOUS NDA 29 sections
BYDUREON HUMAN PRESCRIPTION DRUG LABEL 1 0310-6530 INJECTION, SUSPENSION, EXTENDED RELEASE 2 mg SUBCUTANEOUS NDA 29 sections
BYDUREON HUMAN PRESCRIPTION DRUG LABEL 1 0310-6530 INJECTION, SUSPENSION, EXTENDED RELEASE 2 mg SUBCUTANEOUS NDA 29 sections
BYDUREON HUMAN PRESCRIPTION DRUG LABEL 1 0310-6530 INJECTION, SUSPENSION, EXTENDED RELEASE 2 mg SUBCUTANEOUS NDA 29 sections
BYDUREON BCise HUMAN PRESCRIPTION DRUG LABEL 1 0310-6540 INJECTION, SUSPENSION, EXTENDED RELEASE 2 mg SUBCUTANEOUS NDA 29 sections
BYDUREON BCise HUMAN PRESCRIPTION DRUG LABEL 1 0310-6540 INJECTION, SUSPENSION, EXTENDED RELEASE 2 mg SUBCUTANEOUS NDA 29 sections
BYDUREON BCise HUMAN PRESCRIPTION DRUG LABEL 1 0310-6540 INJECTION, SUSPENSION, EXTENDED RELEASE 2 mg SUBCUTANEOUS NDA 29 sections
BYDUREON BCise HUMAN PRESCRIPTION DRUG LABEL 1 0310-6540 INJECTION, SUSPENSION, EXTENDED RELEASE 2 mg SUBCUTANEOUS NDA 29 sections
BYETTA HUMAN PRESCRIPTION DRUG LABEL 1 54868-5384 INJECTION 250 ug SUBCUTANEOUS NDA 30 sections